Literature DB >> 8314337

Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer.

W N Dinjens1, M M van der Weiden, F H Schroeder, F T Bosman, J Trapman.   

Abstract

We have studied the frequency of mutations in the p53 gene in human prostate cancer. The investigated material consisted of 20 primary-tumor tissue specimens, obtained by transurethral resection and tissue specimens of 15 lymph-node metastases, obtained at total prostatectomy. The applied methods encompassed immunohistochemistry on frozen sections, using the monoclonal antibody PAb 1801, and single-strand conformation polymorphism (SSCP) analysis, after amplification of single exon sequences by PCR, on exons 5 to 8 of the p53 gene. The mutations, leading to aberrantly migrating bands in the PCR-SSCP analysis, were identified by direct sequencing of the PCR product. Immunohistochemical and PCR-SSCP analysis were completely confirmative. In the primary tumors, mutations were found in 10% of the specimens (codons 232 and 273), and in lymph-node metastases in 15% of the specimens (codons 248 and 273). In one case (codon 273), the same mutation was found both in the primary tumor and in the lymph-node metastasis. Our results show that p53 mutations are infrequent in both primary and metastatic prostate tumors. In addition, they indicate that there is no strict correlation between p53 mutation and tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8314337     DOI: 10.1002/ijc.2910560504

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.

Authors:  J T Isaacs
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 2.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

3.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.

Authors:  N Konishi; Y Hiasa; H Matsuda; M Tao; T Tsuzuki; I Hayashi; Y Kitahori; T Shiraishi; R Yatani; J Shimazaki
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

4.  A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.

Authors:  J Kim; M Roh; I Doubinskaia; G N Algarroba; I-E A Eltoum; S A Abdulkadir
Journal:  Oncogene       Date:  2011-06-20       Impact factor: 9.867

5.  P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.

Authors:  R Dahiya; G Deng; K M Chen; R M Chui; P C Haughney; P Narayan
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

6.  A microdissection approach to detect molecular markers during progression of prostate cancer.

Authors:  P Berthon; T Dimitrov; M Stower; O Cussenot; N J Maitland
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

7.  p53 gene mutations in human prostate cancers in Japan: different mutation spectra between Japan and western countries.

Authors:  M Watanabe; T Ushijima; H Kakiuchi; T Shiraishi; R Yatani; J Shimazaki; T Kotake; T Sugimura; M Nagao
Journal:  Jpn J Cancer Res       Date:  1994-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.